InterVene Inc., a Mountain View, CA-based developer of a non-implantable, catheter-based, vein valve creation therapy, closed a $5.9m in Series A funding.
The round was led by Boston Scientific (NYSE: BSX) with participation from North Texas Angels Network, Green Park and Golf Ventures, LaunchCapital and a syndicate of angel investors.
The company intends to use the funds to support a two-stage clinical trial.
Led by CEO Fletcher Wilson, InterVene develops a non-implantable, catheter-based, vein valve creation therapy designed to treat chronic venous insufficiency (CVI) in the deep veins.
The company arose out of the Stanford Biodesign Fellowship and then joined The Fogarty Institute for Innovation.
FinSMEs
23/03/2015